Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Inspyr Therapeutics, Inc. | v308424_ex99-1.htm |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 3, 2012 (March 29, 2012)
GENSPERA, INC.
(Exact name of registrant as specified in Charter)
| Delaware | 0001421204 | 20-0438951 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File No.) | (IRS Employee Identification No.) |
2511 N Loop 1604 W, Suite 204
San Antonio, TX 78258
(Address of Principal Executive Offices)
210-479-8112
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On March 29, 2012, GenSpera, Inc. (the “Company”) announced the completion of the dose-escalation component of its ongoing Phase I trial, the initiation of the Phase 1b component of the trial and that the Company is preparing to commence Phase II clinical studies of its chemotherapeutic agent, G-202. A copy of the press release is attached to this report as Exhibit 99.01.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 3, 2012
| GenSpera, Inc. | ||
| By: | /s/ Craig Dionne | |
| Craig Dionne Chief Executive Officer | ||
INDEX OF EXHIBITS
| Incorporated by Reference | ||||||||||||
|
Exhibit No. |
Description |
Filed Herewith |
Form |
Exhibit No. |
File No. |
Filing Date | ||||||
| 99.01 | Press Release dated March 29, 2012 | * | ||||||||||